IN8bio to Present at April Investor and Scientific Conferences

Rhea-AI Summary

IN8bio, a clinical-stage biopharmaceutical company, announced its presentations for upcoming April conferences. At the AACR Annual Meeting 2022 in New Orleans, Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, and Dr. Lei Ding will address drug-resistant immunotherapy on April 13. Additionally, CEO William Ho will participate in a panel at the BIO Alabama Annual Conference 2022 on April 25.

IN8bio specializes in developing gamma-delta T cell therapies for tumors and is currently running Phase 1 trials for INB-200 and INB-100.

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced April conference presentations:

• American Association for Cancer Research (AACR) Annual Meeting 2022 (New Orleans), April 8 – 13, 2022
  • Lawrence Lamb, Ph.D., CSO, will present “Maintenance-Phase Temozolomide as a Lymphodepletion Platform for Intracranial Adoptive γδ T Cell-Based Therapy in Primary High-Grade Gliomas”
  • April 11, 2022, 9:00 – 12:30 p.m. CDT
  • Visit https://bit.ly/3JRDUum
    
    
  • Lei Ding, Ph.D., Lead Program Scientist, will present “Dual Chlorotoxin and Methylguanine-DNA Methyltransferase (MGMT) γδ T Cells for Drug Resistant Immunotherapy”
  • April 13, 2022, 9:00 – 12:30 p.m. CDT
  • Visit https://bit.ly/3JQF1KV
    

• BIO Alabama Annual Conference 2022 (Birmingham) April 25 – 26, 2022
  
  • William Ho, CEO, will be on a panel highlighting successful Alabama biotechnology companies.
  • April 25, 2022
  • Visit https://bit.ly/3DtKW6h

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Contacts
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6438
kmrochlin@in8bio.com

Investors:
Solebury Trout
David Buck
+1 646.378.2927
dbuck@soleburytrout.com

Media:
Burns McClellan, Inc.
Katie Larch / Robert Flamm, Ph.D.
klarch@burnsmc.com / rflamm@burnsmc.com

FAQ

What presentations will IN8bio have at the AACR Annual Meeting 2022?

IN8bio will present two studies: Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, while Dr. Lei Ding will address drug-resistant immunotherapy on April 13.

When is the BIO Alabama Annual Conference 2022?

The BIO Alabama Annual Conference 2022 will take place from April 25 to 26, 2022.

What is IN8bio focusing on in its clinical trials?

IN8bio focuses on gamma-delta T cell therapies for treating various tumors, with ongoing Phase 1 trials for INB-200 and INB-100.

Where can I find more information about IN8bio?

More information about IN8bio and its programs can be found on their official website at www.IN8bio.com.

What is the significance of the DeltEx platform for IN8bio?

The DeltEx platform is crucial for developing innovative gamma-delta T cell therapies that target solid and liquid tumors.